background
sarscov
etiolog
agent
sever
acut
respiratori
syndrom
understand
antibodi
respons
viral
compon
import
diagnosi
vaccin
develop
object
spectrum
sarsspecif
antibodi
profil
sar
patient
investig
day
onset
symptom
studi
design
serial
serum
sampl
sar
patient
isol
day
onset
symptom
test
antivir
igg
igm
indirect
immunofluoresc
test
ifa
antinucleocaspid
antibodi
elisa
test
viral
neutral
result
antivir
igg
antinucleocaspid
antibodi
observ
patient
day
onset
symptom
patient
day
thereaft
antivir
antibodi
igm
detect
maxim
day
later
igg
class
igm
antibodi
declin
becam
undetect
day
onset
symptom
neutral
viral
antibodi
demonstr
sera
patient
sar
symptom
conclus
antivir
igg
igm
antinucleocaspid
antibodi
detect
day
patient
onset
sar
symptom
antivir
igm
antibodi
disappear
earlier
igg
viral
neutral
demonstr
sera
convalesc
patient
sever
acut
respiratori
syndrom
sar
first
report
guangdong
provinc
china
novemb
follow
spread
countri
worldwid
lee
et
al
newli
isol
coronaviru
sarscov
found
etiolog
agent
sar
drosten
et
al
genom
viru
soon
sequenc
marra
et
al
develop
vaccin
sarscov
subsequ
pursu
sever
laboratori
great
import
identifi
characterist
host
antibodi
sar
viru
compon
aid
vaccin
develop
diagnosi
viral
infect
chen
et
al
li
et
al
correspond
author
tel
fax
email
address
caoc
nicbmiaccn
c
cao
fourteen
patient
age
year
old
median
year
diagnos
probabl
sar
patient
base
criteria
februari
serial
serum
sampl
collect
day
onset
symptom
subject
antibodi
analysi
antivir
antibodi
igg
igm
assay
indirect
fluoresc
kit
develop
beij
institut
microbiolog
epidemiolog
approv
state
drug
administr
china
si
et
al
l
dilut
sera
greater
dilut
ad
onto
slide
contain
monolay
sarscovinfect
vero
cell
noninfect
vero
cell
neg
control
slide
incub
c
min
wash
three
time
pb
phosphat
buffer
salin
fitclabel
antihuman
igg
fitclabel
antihuman
igm
ad
min
slide
wash
fluoresc
detect
zeiss
axiovert
microscop
dilut
cut
antinucleocaspid
n
protein
np
total
ig
assay
antigencaptur
elisa
acelisa
codevelop
sinaamerican
biotechnolog
co
ltd
beij
institut
biotechnolog
shi
et
al
assay
l
serum
sampl
ad
well
coat
recombin
n
protein
plate
incub
c
min
wash
five
time
pb
contain
tween
l
hrp
hors
radish
peroxidas
conjug
n
protein
ad
plate
incub
anoth
min
follow
wash
l
tmb
substrat
solut
mgml
tetramethylbenzidin
hydrochlorid
h
acet
buffer
ph
ad
incub
c
min
reaction
termin
ad
l
n
sulfur
acid
absorb
nm
determin
maximum
dilut
serum
posit
signal
obtain
ifa
absorb
nm
wavelength
greater
cutoff
valu
given
defin
antibodi
titer
data
analyz
softwar
geometr
mean
seroposit
sampl
employ
statist
neutral
antibodi
assay
follow
protocol
ml
dilut
serum
mix
ml
dmem
medium
contain
sarscov
strain
viru
incub
c
h
waterbath
mixtur
aliquot
well
l
vero
cell
monolay
grown
microtit
plate
plate
incub
c
co
day
highest
dilut
serum
well
protect
viral
cytopath
effect
consid
neutral
titer
seroconvers
observ
patient
either
antivir
igg
fia
antigen
captur
antin
protein
assay
day
onset
symptom
contrast
antivir
igm
detect
patient
day
patient
day
onset
symptom
comparison
antivir
igg
antin
protein
antibodi
detect
patient
day
onset
symptom
antivir
igm
shown
neg
patient
day
day
post
diseas
onset
respect
result
may
indic
antivir
igg
may
correl
better
viral
neutral
also
recombin
nucleocaspid
protein
base
antigencaptur
elisa
least
sensit
antivir
igg
ifa
assay
antivir
igg
antinucleocaspid
antibodi
detect
earlier
antivir
igm
antibodi
highest
antibodi
titer
reach
day
antivir
igg
day
antin
protein
onset
symptom
titer
decreas
slowli
time
point
high
titer
antibodi
observ
patient
day
onset
symptom
geometr
mean
valu
antibodi
shown
fig
contrast
significantli
lower
titer
antivir
igm
antibodi
found
peak
titer
day
moreov
antivir
igm
could
detect
patient
day
onset
symptom
understand
potenti
viral
neutral
convalesc
patient
infect
viru
neutral
antibodi
assay
six
convalesc
patient
sera
collect
day
onset
symptom
found
six
patient
neutral
antibodi
detect
geometr
mean
neutral
titer
day
respect
data
indic
viral
neutral
featur
sar
infect
durat
viral
neutral
greater
month
